Additionally, Abbott laboratories using SAR by NMR and structure based drug design have recently developed a drug that is a highly potent, selective, anti-cancer agent that would potentially overcome Bcl-xL mediated thrombocytopenia observed with ABT-263 [114]. Here, BCL2L1 is linked to cancer.